RESUMEN
BACKGROUND: Positive fluid balance (FB) has been linked to adverse clinical outcomes. We performed this study to explore the relationship between perioperative fluid balance and acute kidney injury (AKI). METHODS: The relationships between FB and AKI were explored using a prospective, observational design. Patients were divided into quartiles based on FB status in the first 24 h from initiation of surgery in order to further explore this relationship. RESULTS: One hundred adult patients undergoing cardiovascular surgery were included in the analysis. The major finding of the study was that positive FB occurred early in the intraoperative period and progressed into the postoperative period and that fluid administration was not clearly associated with any identifiable volume-sensitive event. The evolution of positive FB preceded the rise in serum creatinine. Progressive severity of positive FB was associated with increased incidence of AKI. The highest quartile FB group had a five-fold increased risk for AKI (adjusted odds ratio 4.98, 95 % confidence interval 1.38-24.10, p = 0.046) compared to the lowest quartile group, higher postoperative peak serum creatinine values (p < 0.001), surgery-related complications (p < 0.001) and intensive care unit (p < 0.001) and hospital length of stay (p = 0.048). CONCLUSIONS: Positive FB was associated with increased incidence of AKI.
Asunto(s)
Lesión Renal Aguda/etiología , Equilibrio Hidroelectrolítico , Lesión Renal Aguda/epidemiología , Adulto , Anciano , Procedimientos Quirúrgicos Cardiovasculares/efectos adversos , Creatinina/sangre , Cuidados Críticos , Femenino , Florida/epidemiología , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Estudios ProspectivosRESUMEN
BACKGROUND: Effective therapeutic agents for the prevention and treatment of acute kidney injury (AKI) after cardiac surgery remain elusive despite the tremendous advances in surgical techniques, technology, and understanding of disease processes. Recent developments and their effect on the incidence of AKI after cardiac surgery are discussed. DATA SOURCES: Published clinical trials in PubMed, strength of evidence assessed by the guidelines of the American Family Physicians. CONCLUSIONS: The definition of AKI has changed, and the focus of interventions has shifted from treatment to prevention to recovery from AKI. Antioxidants and biological agents have been added to classic armaments of hydration and diuretics in addition to tighter metabolic control to prevent AKI. Although the treatment options remain unsatisfactory, a lot of progress nevertheless continues to be made in the prevention and treatment of AKI.
Asunto(s)
Lesión Renal Aguda/prevención & control , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Procedimientos Quirúrgicos Cardíacos/métodos , Fármacos Cardiovasculares/administración & dosificación , Puente de Arteria Coronaria Off-Pump , Fluidoterapia , Hipotermia Inducida , Lesión Renal Aguda/etiología , Lesión Renal Aguda/metabolismo , Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Antioxidantes/administración & dosificación , Glucemia/metabolismo , Transfusión Sanguínea , Ensayos Clínicos como Asunto , Medios de Contraste/administración & dosificación , Medios de Contraste/efectos adversos , Diuréticos/administración & dosificación , Dopamina/administración & dosificación , Fenoldopam/administración & dosificación , Fluidoterapia/métodos , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Contrapulsador Intraaórtico , Péptidos Natriuréticos/administración & dosificación , Atención Perioperativa/métodos , Periodo Perioperatorio , Vasodilatadores/administración & dosificaciónRESUMEN
Experimental data suggest that the B-cell antigen CD20 may play a significant role in the pathogenesis of many diseases including glomerular diseases. These and other findings underpin the central concept of B-cell-depleting therapies that target CD20 antigen as treatments for lupus nephritis, idiopathic membranous nephropathy, focal segmental glomerulosclerosis, cryglobulinemic glomerulonephritis, antibody mediated renal allograft rejection and recurrent glomerulonephritis in renal allograft. Use of rituximab as a B-cell depleting therapy has been associated with clinical improvement and has emerged as a possible adjunct or alternative treatment option in this field of nephrology.
Asunto(s)
Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Rechazo de Injerto/prevención & control , Factores Inmunológicos/uso terapéutico , Enfermedades Renales/terapia , Trasplante de Riñón , Depleción Linfocítica/métodos , Aloinjertos , Anticuerpos Monoclonales de Origen Murino/inmunología , Linfocitos B/inmunología , Linfocitos B/patología , Rechazo de Injerto/inmunología , Rechazo de Injerto/patología , Humanos , Factores Inmunológicos/inmunología , Enfermedades Renales/inmunología , Enfermedades Renales/patología , RituximabRESUMEN
BACKGROUND: Slow continuous ultrafiltration (SCUF) is a safe and efficient treatment for fluid overload in patients who are hemodynamically unstable, have low urine output, and are not in need of dialysis or hemofiltration for solute clearance. Sustained anticoagulation is required for these long treatments, thus posing clinically challenges for patients having contraindications to systemic anticoagulation with heparin. Regional citrate anticoagulation would be an alternative option; however, we believed that this would be problematic due to citrate kinetics that predicted the development of metabolic alkalosis. METHODS: In that patients' serum bicarbonate reached 45 mEq/L and arterial pH rose to 7.59 after just 3 days of SCUF, we developed equations to study this phenomenon. We report here the acid-base balance calculations quantifying base accumulation in SCUF compared to continuous venovenous hemofiltration (CVVH). RESULTS: This kinetic approach demonstrates the importance of accounting for the high citrate clearance into CVVH hemofiltrate, which prevents development of the alkalosis seen with the relatively low ultrafiltration rates in SCUF: there was net bicarbonate accumulation of â¼1400 mmol/day with SCUF, compared to 664 to as low as 274 mmol/day during CVVH. The calculations underscore the importance of the relative fluid flow rates as well as the bicarbonate and citrate levels in the various infused solutions. We also discuss how citrate's acid-base effects are potentially complicated by metabolism via gluconeogenic and ketone body pathways. CONCLUSIONS: These acid-base balance findings emphasize why clinicians must be mindful of the risk of metabolic alkalosis when using continuous renal replacement therapy modalities with low rates of ultrafiltration, which thereby presents a contraindication for using citrate anticoagulation for SCUF.
RESUMEN
BACKGROUND: We hypothesized that post-operative serum uric acid (SUA) may be associated with acute kidney injury (AKI). METHODS: In this prospective, observational study, the relationships between SUA, urine neutrophil gelatinase-associated lipocalin (uNGAL) and interleukin-18 (uIL-18), serum monocyte chemoattractant protein-1 (sMCP-1) and tumor necrosis factor-alpha (sTNF-alpha), and incidence of AKI were determined. SUA were divided into tertiles and their association with AKI investigated. RESULTS: A total of 100 cardiac surgery patients were included for analyses. The 1st, 2nd, and 3rd SUA tertiles were associated with 15.1%, 11.7%, and 54.5% incidence of AKI, respectively. The 3rd SUA tertile, compared to the referent 1st tertile, was associated with an eightfold (OR 8.38, CI95% 2.13-33.05, p=0.002) increased risk for AKI. Patients with AKI on post-operative day 1 (n=11) were then excluded for the purpose of determining the predictive value of SUA to diagnose AKI on postoperative day 2 and during hospital stay. In comparison to the referent 1st tertile, the 3rd tertile SUA was associated with an eightfold increased risk for AKI on post-operative day 2 (adjusted OR 7.94, CI95% 1.50-42.08, P=.015) and a five-fold increased risk for AKI during hospital stay (OR 4.83, CI95% 1.21-19.20, P=.025), respectively. SUA (Area Under Curve, AUC 0.77 (CI95% 0.66-0.88, P<.001), serum creatinine (0.73, CI95% 0.62-0.84, P<.001) and sTNF-alpha (0.76, CI95% 0.65-0.87, P<.001) had the best diagnostic performance measured by the Receiver Operating Characteristics curves. CONCLUSIONS: We conclude that post-operative SUA is associated with an increased risk for AKI and compares well to conventional markers of AKI.
Asunto(s)
Lesión Renal Aguda/sangre , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Ácido Úrico/sangre , Lesión Renal Aguda/epidemiología , Lesión Renal Aguda/orina , Proteínas de Fase Aguda/orina , Biomarcadores/sangre , Biomarcadores/orina , Quimiocina CCL2/sangre , Distribución de Chi-Cuadrado , Femenino , Florida/epidemiología , Humanos , Incidencia , Interleucina-18/orina , Tiempo de Internación , Lipocalina 2 , Lipocalinas/orina , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Estudios Prospectivos , Proteínas Proto-Oncogénicas/orina , Curva ROC , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo , Factor de Necrosis Tumoral alfa/sangreRESUMEN
Acute kidney injury in patients undergoing cardiovascular surgery is a complex problem with associated increased risks for dialysis, short- and long-term mortality, and progression to end-stage renal disease. Interventions to prevent and treat renal complications in this cohort have seldom been uniformly satisfactory due to the differences in strategies for intervention, drug doses and duration of treatment, baseline renal functions, and population studied. Nonetheless, significant advances have been made and include recognition of the effect of preexisting organ dysfunction on renal outcomes, reassessment of existing therapeutic interventions, and exploration of the feasibility of newer agents to prevent and treat acute kidney injury in cardiovascular surgery patients. This article briefly reviews several of these issues with an emphasis on recent clinical trials in this cohort.